Veeva to Acquire Crossix


Applied Clinical Trials

Veeva Systems and Crossix Solutions have announced that they have entered into a definitive agreement for Veeva to acquire Crossix. Crossix will operate as an independent business unit under its current brand led by Crossix CEO Asaf Evenhaim.

Crossix delivers privacy-safe US patient data and an analytics platform to help maximize media and marketing effectiveness.

“Crossix has been the pioneer in patient data, privacy, and analytics,” said Veeva founder and CEO Peter Gassner. “As we look toward the future of a more patient-centric healthcare system, Asaf and I are excited to join forces to help the industry deliver better patient outcomes.”

The Crossix analytics platform provides technology that connects health and non-health data for more than 300 million US patients to drive greater marketing effectiveness. Data includes Rx, OTC, clinical, claims, consumer, hospital, media data, and more – all of which are protected by privacy safeguards.

“Veeva’s acquisition of Crossix is great for our customers and employees. It allows Crossix to join a proven technology leader and advance our solutions for the industry,” said Mr. Evenhaim. “Most importantly, our companies share a commitment to innovation and have a common way of working that values integrity, long-term thinking, and customer success.”

Crossix will remain headquartered in New York and continue operations in Israel and Belarus.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.